Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
23.27
-0.96 (-3.98%)
Streaming Delayed Price
Updated: 2:13 PM EDT, Sep 21, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arvinas Inc
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP)
From
Arvinas Inc.
Via
GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
July 06, 2023
Collaboration expands Carrick’s clinical-stage Oncology program
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
Arvinas Announces Changes to its Board of Directors
June 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
June 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Stifel Targeted Oncology Day
April 21, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
April 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
February 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 23, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
February 06, 2023
From
Arvinas Inc.
Via
GlobeNewswire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
January 13, 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Via
MarketBeat
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Changes to its Board of Directors
December 16, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
November 22, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Upcoming Conferences
November 01, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
October 03, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community
September 30, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
October 27, 2022
Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field of targeted protein degradation
From
Arvinas Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.